Literature DB >> 33099577

The neuroendocrine modulation of global DNA methylation in neuropsychiatric disorders.

Diego L Rovaris1,2,3, Claiton H D Bau4,5,6, Diana Müller7,1,2, Eugenio Horacio Grevet1,2,8, Bruna Santos da Silva7,1,2, Mariele Feiffer Charão9.   

Abstract

There is an increasing body of knowledge on the influence of differential DNA methylation of specific genomic regions in psychiatric disorders. However, fewer studies have addressed global DNA methylation (GMe) levels. GMe is an estimative of biological functioning that is regulated by pervasive mechanisms able to capture the big picture of metabolic and environmental influences upon gene expression. In the present perspective article, we highlighted evidence for the relationships between cortisol and sex hormones and GMe in psychiatric disorders. We argue that the far-reaching effects of cortisol and sexual hormones on GMe may lie on the pathways linking stress and mental health. Further research on these endocrine-epigenetic links may help to explain the role of environmental stress as well as sex differences in the prevalence of psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33099577     DOI: 10.1038/s41380-020-00924-y

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  30 in total

1.  Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset.

Authors:  Philippe A Melas; Maria Rogdaki; Urban Ösby; Martin Schalling; Catharina Lavebratt; Tomas J Ekström
Journal:  FASEB J       Date:  2012-03-16       Impact factor: 5.191

2.  Reversing DNA methylation: mechanisms, genomics, and biological functions.

Authors:  Hao Wu; Yi Zhang
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

3.  Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: a potential link between epigenetics and schizophrenia.

Authors:  Morihiro Shimabukuro; Tsukasa Sasaki; Akira Imamura; Takahiro Tsujita; Chiaki Fuke; Tadashi Umekage; Mamoru Tochigi; Kennichi Hiramatsu; Tetsuji Miyazaki; Takaya Oda; Jun Sugimoto; Yoshihiro Jinno; Yuji Okazaki
Journal:  J Psychiatr Res       Date:  2006-10-17       Impact factor: 4.791

4.  Variation in global DNA hydroxymethylation with age associated with schizophrenia.

Authors:  Tingyun Jiang; Lu Zong; Lin Zhou; Yu Hou; Lulu Zhang; Xianzhen Zheng; Hongying Han; Shufen Li; Wenwei Zhang; Jian Zhang; Cong Deng; Yanbin Jia; Cunyou Zhao
Journal:  Psychiatry Res       Date:  2017-08-16       Impact factor: 3.222

Review 5.  Gene-environment interaction and psychiatric disorders: Review and future directions.

Authors:  Elham Assary; John Paul Vincent; Robert Keers; Michael Pluess
Journal:  Semin Cell Dev Biol       Date:  2017-10-18       Impact factor: 7.727

Review 6.  The DNA methyltransferase family: a versatile toolkit for epigenetic regulation.

Authors:  Frank Lyko
Journal:  Nat Rev Genet       Date:  2017-10-16       Impact factor: 53.242

7.  Hypomethylation of LINE-1 elements in schizophrenia and bipolar disorder.

Authors:  Shufen Li; Qiong Yang; Yu Hou; Tingyun Jiang; Lu Zong; Zhongju Wang; Xia Luo; Wenquan Liang; Hu Zhao; Yuping Ning; Cunyou Zhao
Journal:  J Psychiatr Res       Date:  2018-10-10       Impact factor: 4.791

Review 8.  Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role.

Authors:  Krista S Crider; Thomas P Yang; Robert J Berry; Lynn B Bailey
Journal:  Adv Nutr       Date:  2012-01-05       Impact factor: 8.701

9.  Global leukocyte DNA methylation is not altered in euthymic bipolar patients.

Authors:  A Bromberg; Y Bersudsky; J Levine; G Agam
Journal:  J Affect Disord       Date:  2009-03-06       Impact factor: 4.839

10.  Decreased global methylation in patients with bipolar disorder who respond to lithium.

Authors:  Aya A Huzayyin; Ana C Andreazza; Gustavo Turecki; Cristiana Cruceanu; Guy A Rouleau; Martin Alda; L Trevor Young
Journal:  Int J Neuropsychopharmacol       Date:  2013-12-17       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.